When it comes to dealmaking, hardball tactics can backfire -- as Sanofi is finding out.
Late Tuesday, the French drugmaker dropped hostile efforts to acquire oncology specialist Medivation after being granted access to its target's confidential data.
The bad news? They're not the only ones: Medivation said it has opened its books to other parties. These include Pfizer, Celgene and Amgen, according to CNBC and Reuters. The fact that it's so coveted means Sanofi likely has no choice but to lift its offer yet again in order to add Xtandi, Medivation's FDA-approved prostate-cancer drug, to its portfolio.
A competitive process could have been avoided from the get-go. Rather than offering $52.50 a share back in April and then attempting to replace Medivation's board after its advances were rejected, Sanofi could have made a bid that was compelling enough to gain the recommendation of that same board. Instead, it established bad blood with management who have spurned its latest offer of $58 a share (plus a contingent value right worth $3 at most) and effectively put Medivation within the grasp of other suitors.
As I wrote in April, Sanofi can afford $70 a share without factoring in synergies -- or well north of that, depending on estimated cost savings. And if the French behemoth chooses not to pay up to strike an accretive deal, it faces punishment by investors who have identified that the company needs to do something to boost its profitability. Its EPS is expected to grow at a compounded annual rate of just 5.6 percent between 2015 and 2020, trailing the sector median of 9.3 percent, according to Oddo Securities.
Medivation may well slip through Sanofi's grips. If so, Sanofi's shareholders can only hope the drugmaker learns from its mistakes.
This column does not necessarily reflect the opinion of Bloomberg LP and its owners.
To contact the author of this story:
Gillian Tan in New York at email@example.com
To contact the editor responsible for this story:
Beth Williams at firstname.lastname@example.org